Skip to main content

Table 3 Characteristics of patients with worsening pre-existing PNS after immunotherapy (cohort 1) or newly diagnosed PNS following immunotherapy (cohort 2)

From: Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Outcome of patients with worsening or newly diagnosed PNSCohort 1 (pre-existing PNS)
n = 8 patients with PNS worsening
Cohort 2 (newly diagnosed PNS)
n = 16 patients
Total
n = 24 patients
Time from initiation of immunotherapy to PNS worsening (cohort 1) or new diagnosis of a PNS (cohort 2), median (range), in months0.9 (0.5–2.8)1.6 (0.5–6.4)1.4 (0.5–6.4)
Antitumor response at time of worsening or newly diagnosed PNS, n (%)
 - CR2 (25)1 (6)3 (13)
 - PR2 (25)5 (31)7 (30)
 - SD2 (25)10 (63)12 (50)
 - PD2 (25)02 (8)
Best overall antitumor response
 - CR2 (25)1 (6)3 (13)
 - PR3 (38)5 (31)8 (33)
 - SD1 (13)8 (50)9 (38)
 - PD2 (25)2 (13)4 (17)
Impact of PNS on immunotherapy, n (%)
 - temporary discontinuation2 (25)4 (25)6 (25)
 - permanent discontinuation5 (62)9 (56)14 (58)
 - no discontinuation1 (13)3 (19)4 (17)
  1. CR Complete response, CTCAE Common Terminology Criteria for Adverse Events, PD Progressive disease, PNS Paraneoplastic syndrome, PR Partial response, SD Stable disease